Their range of products and services includes tumor diagnosis, personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is committed to advancing precision medicine by providing early, accurate, and informative diagnoses to patients. They have developed liquid biopsy analysis reagents and software, focusing on methylation haplotypes in cell-free DNA. With their PanSeer assay, Singlera can detect cancer up to four years earlier than conventional methods, using a targeted methylation assay and efficient bioinformatics analysis. Their ColonES assay demonstrates high sensitivity and specificity for colorectal cancer detection. Singlera is currently seeking potential collaborators to bring their revolutionary technology to market.